Stem Cell Clinic

Cell Culture Protein Surface Coating Market Competitive Analysis and Forecast 2017-2025 – Latest Herald

By Stem Cell Medicine

Global Cell Culture Protein Surface Coating Market: Snapshot

The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions. These cells are used to develop model systems for study and research of cellular structures as well as for drug discovery and genetic engineering.

Thus, the growing scope of cell cultures in various applications has led to the development of the 3D cell culture technique, which has been considered one of the key factors responsible for the overall past development of the cell culture protein surface coatings market. Earlier, only a meager percentage of researchers preferred using 3D cell culture technique for drug discovery. However, there has been a dynamic shift from the traditional methods to the current cell culture methods.

Moreover, commercial production of drugs and biologics such as proteins, antibodies, and vaccines using cell culture has helped expand the scope of the latter in the global market. Commercial production has provided extensive business opportunities to manufacturers in the global market. Diverse applications of stem cells such as development of bone grafts and artificial tissue are also expected to fuel the demand for cell culture protein surface coatings over the forecast period. In addition, increasing cell culture applications in toxicology studies and cell-based assays are further pushing the growth of the market.

Global Cell Culture Protein Surface Coating Market: Overview

Cell culture protein surface coatings help in improving cell attachment, growth, and differentiation. They facilitate consistent performance in various cell-based assays and in-vitro culture by improving cell adhesion. A variety of adhesion proteins and other biological materials derived from various sources are being used to enhance performance in cell culture, especially in cell lines that are hard to attach, such as transfected cells. The major types of cell culture are animal-derived protein, human-derived protein, synthetic protein, and plant-derived protein. Good cell attachment has gained increased significance in recent years for improving the recovery of cells from frozen cultures and increasing the stability of attached surfaces. With constant advances in stem cell therapies, a number of advanced protein surface coatings have emerged to study stem cells and to further the potential of regenerative medicine. These developments have positively affected the growth of the global cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Key Trends

The increasing focus of numerous biotechnology companies and research laboratories on stem cell research to develop therapies for a range of chronic diseases is a key factor propelling the cell culture protein market. Considerable investment by the governments of various countries to fund several R&D activities related to regenerative medicine has fuelled the market. Coupled with this, the rising demand for biopharmaceutical products such as antibodies, vaccines, and drugs has stimulated the demand for cell culture protein surface coatings. The growing research on stem cells for finding therapies for various cardiovascular and neurological diseases is expected to boost the market in the coming years. The growing prominence of 3D cell culture over 2D cell cultures is expected to unlock exciting opportunities in the cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Market Potential

The American Heart Association (AHA), together with the Paul G. Allen Frontiers Group, announced in April, 2017 two grantseach worth US$1.5 millionto scientists working on cardiovascular extracellular matrix (ECM) research. Interested researchers have to apply for grants by May 10, and each of the two winners will be entitled to the magnanimous sum.

The ECM regulates all vital cell functions and is considered a highly useful biomaterial for investigators. This can be applied as a stable coating to be used in a variety of cell cultures. The initiative focused on investigating the role of ECM in the initiation and progression of a number of cardiovascular diseases, such as hypertensive heart disease, ischemic heart disease, cardiomyopathies, congenital cardiovascular malformations, and atherosclerosis and vascular diseases. The funding will further the investigation into the diagnosis, prevention, and treatment of cardiovascular diseases. One of the most commonly used protein surface coatings used in ECM is collagen, which facilitates cell adherence, growth, migration, differentiation, and proliferation. The major research initiatives, opine the AHA, will be greatly useful in setting up a new paradigm in research in cell structure in biosciences.

Global Cell Culture Protein Surface Coating Market: Regional Outlook

North America is a prominent market for cell culture protein surface coatings and is expected to exhibit significant growth over the forecast period. The impressive growth in the regional market is attributed to the presence of a robust healthcare infrastructure and considerable advances in stem cell research. In addition, the soaring demand for regenerative medicines for a range of autoimmune therapies is expected to fuel the demand for surface coatings for improving the performance of in-vivo culture.

The Asia Pacific market for cell culture protein surface coating is poised to offer lucrative avenues for players in the market. Favorable regulations for biologics development and a burgeoning biotechnology industry are the factors expected to lead to substantial demand for cell culture protein surface coatings.

Global Cell Culture Protein Surface Coating Market: Competitive Analysis

The market is fairly competitive due to the presence of a large number of regional and global vendors. Leading vendors are actively focused on providing solutions having cell attachment ability and promoting in-vitro cell functions for a variety of cell types to gain competitive edge over others. Leading players operating in this market include Sigma-Aldrich Corporation, Agilent Technologies, Thermo Fisher Scientific, EMD Millipore, Corning Incorporated, Biomedtech Laboratories Inc., Neuvitro Corporation, and Progen Biotechnik GmbH.

The rest is here:
Cell Culture Protein Surface Coating Market Competitive Analysis and Forecast 2017-2025 - Latest Herald

Five UC San Diego Professors Elected to National Academy of Sciences – UC San Diego Health

By Stem Cell Medical Center

Clockwise from top left, Dmitri Basov, Lawrence Goldstein, Terence Hwa, Clifford Kubiak, Kimberly Prather

The National Academy of Sciences elected five professors affiliated with the University of California San Diego to membership in the prestigious National Academy of Sciences, one of the highest honors bestowed on U.S. scientists and engineers.

UC San Diego faculty members Dmitri Basov, Lawrence Goldstein, Terence Hwa, Clifford Kubiak, and Kimberly Prather whose work spans fields ranging from medicine and biological sciences to atmospheric chemistry and physics were recognized Monday in recognition of their distinguished and continuing achievements in original research, according to the Academy. They were among 120 American scientists and 26 international members named this year.

For a young institution such as ours, having five professors inducted into the National Academy of Sciences speaks volumes of the innovative and visionary nature of this university and our well-respected and accomplished faculty, said UC San Diego Chancellor Pradeep K. Khosla. I am proud to see the career accomplishments of these five professors recognized on such a distinguished national platform, alongside the countrys other leading researchers.

This brings the total number of National Academy of Sciences members from UC San Diego to 86.

Dmitri Basov is an affiliated UC San Diego professor in the Department of Physics, where he served as chair between 2010 and 2015. He is also a Higgins professor in the Department of Physics at Columbia University, where he is the principal investigator of the Basov Infrared Laboratory, the director of the DOE Energy Frontiers Research Center on Programmable Quantum Materials and co-director of the Max Planck Society New York Center for Nonequilibrium Quantum Phenomena. His research interests include physics of quantum materials, superconductivity, two-dimensional materials and infrared nano-optics. Basov has received numerous prizes and awards including a Sloan Fellowship (1999), the Genzel Prize (2014), a Humboldt research award (2009), the Frank Isakson Prize, American Physical Society (2012), Moore Investigator (2014), the K.J. Button Prize (2019) and the Vannevar Bush Faculty Fellowship (U.S. Department of Defense, 2019).

Basov earned his PhD at the Lebedev Physical Institute of the Russian Academy of Sciences (1991). He served as postdoctoral research associate at McMaster University (1992-96) and as an assistant physicist at Brookhaven National Laboratory (1996) before joining UC San Diego.

Lawrence Goldstein, PhD, is Distinguished Professor in the Department of Cellular and Molecular Medicine and Department of Neurosciences in the UC San Diego School of Medicine. He founded and directed the UC San Diego Stem Cell Program and the Sanford Stem Cell Clinical Center at UC San Diego Health and is founding scientific director of the Sanford Consortium for Regenerative Medicine. He was instrumental in the development and passage of Proposition 71 in 2004, which created an unprecedented $3 billion fund and infrastructure for stem cell medical research in California.

For more than 25 years, Goldsteins research focus has been to unravel how molecular motors interact with and control the behavior of axonal vesicles in neurons, and how defects in these processes underlie neurological conditions, such as Alzheimers disease (AD).In 2012, his lab was the first to create stem cell-derived in vitro neurons of sporadic and hereditary AD, giving researchers a much-needed method for studying the diseases causes and pathologies and a new tool for developing and testing drugs to treat a disorder that afflicts 5.4 million Americans.

More recently, this work has led to the identification of new cellular targets in AD drug development and a deeper understanding of AD genetics and disease progression. He is among the nations leading scientific figures in promoting AD research and evidence-based treatments.

Terence Hwa is the Presidential Chair and Distinguished Professor in the Department of Physics with a joint appointment in the Division of Biological Sciences. Trained in theoretical physics, Hwa launched a biology wet-lab 15 years ago and developed a unique quantitative approach to studying bacterial physiology. During this time, the Hwa Research Group established a number of bacterial growth laws and formulated a principle of proteomic resource allocation. This line of study culminated in a theory of bacterial growth control, accurately predicting bacterial behaviors and gene expression for a variety of environmental and genetic perturbations, and resolving a number of long-standing mysteries in microbiology. Hwas research team continues to extend its quantitative approaches to characterize bacterial species singly and in consortium, to uncover underlying principles governing the spatiotemporal dynamics of microbial communities.

Hwa is a champion of interdisciplinary research. In 2001, he launched an extended program at the Kavli Institute of Theoretical Physics in Santa Barbara, which has been regarded as a watershed event in bringing physicists to post-genome biology. He is also the founder and co-director of the Quantitative Biology specialization program at UC San Diego. Hwa received fellowships and awards from the Sloan, Beckman, Guggenheim and Burroughs-Wellcome Foundations, and is a Fellow of the American Physical Society and the American Academy of Microbiology. Hwa received his PhD in physics from MIT. After postdoctoral research at Harvard University in condensed-matter physics, he joined UC San Diegos physics faculty in 1995.

Clifford Kubiak is a Distinguished Professor and former chair of the Department of Chemistry and Biochemistry, who holds the Harold C. Urey Chair in Chemistry. His Kubiak Research Group at UC San Diego is especially known for its work on developing catalysts for the electrochemical reduction of carbon dioxide. Kubiak is also a fellow of the American Academy of Arts and Sciences and the American Chemical Society (ACS). He has received several awards including the prestigious ACS Award in Organometallic Chemistry (2018), the Tolman Medal (2018), the Basolo Medal for Outstanding Research in Inorganic Chemistry (2015), the Inter-American Photochemical Society, Award in Photochemistry (2013) and the ACS Award in Inorganic Chemistry (2012). Kubiak has held visiting appointments at Tohoku University, University of Chicago and University of Erlangen, and he was a visiting associate in chemistry at the Joint Center for Artificial Photosynthesis at Caltech. He has served on the Editorial Advisory Boards of Accounts of Chemical Research, Inorganic Chemistry and Materials Science in Semiconductor Processing. He is the author of more than 290 scientific articles.

Before joining UC San Diego in 1998, Kubiak was a faculty member at Purdue University (1982-98). Before that he was a postdoctoral associate with Mark S. Wrighton at MIT (1980-81). He received his PhD in chemistry from the University of Rochester (1980), where he worked with Richard Eisenberg.

Kimberly Prather is a Distinguished Professor who holds a joint appointment between UC San Diegos Scripps Institution of Oceanography and the Department of Chemistry and Biochemistry. Prathers research focuses on understanding the influence of atmospheric aerosols on clouds, human health, and climate. Early in her career, she developed a technique known as aerosol time-of-flight mass spectrometry that is widely used in atmospheric field studies around the world to determine the origin and chemistry of aerosols. She is the founding director of the National Science Foundation Center for Aerosol Impacts on Chemistry of the Environment (CAICE), the largest federally funded center in the history of UC San Diego. CAICE researchers replicate ocean/atmosphere interactions in a laboratory setting to study the influence of ocean biology on atmospheric chemistry, clouds, and climate.

Prather joined UC San Diego in 2001. She was elected as a member of the American Academy of Arts and Sciences and a fellow of the American Geophysical Union in 2010. In 2019, she became the first woman at UC San Diego to be elected as a member of the National Academy of Engineering. Previously this year, she won the 2020 Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry from the American Chemical Society. She received her PhD in chemistry from the University of California, Davis.

View original post here:
Five UC San Diego Professors Elected to National Academy of Sciences - UC San Diego Health

Suffering from ED? Discover how our combined treatments of Hormone Balancing and FDA Approved Acoustic Wave Pulse Therapy Ends Your ED – Magazine of…

By Stem Cell Medical Center

More than 30 million men are suffering from impotence or erectile dysfunction in the United States.Many men find it difficult to discuss a sexual health problem such as ED. However, its important to discuss your ED openly and honestly with your doctor.Complications resulting from erectile dysfunction can include: an unsatisfactory sex life, stress or anxiety, embarrassment or low self-esteem, relationship problems, the inability to get your partner pregnant.TreatmentsMany men prefer taking pills instead of surgery. Pills are the short-term solution.Valencia Medical Center offers new medical breakthrough procedure that leads to more long-term treatment for erectile dysfunction. Using acoustic wave therapy to repair blood vessels to the genitals.Treatment principals:Initial office visit evaluates your condition and order a comprehensive blood testing including hormone test. The result indicates if any hormonal imbalance such as testosterone exist.The first part of the treatment plan is to restore the hormone deficiency which is essential to recovery of sexual function. Hormone Pellet Therapy is the most effective restoration to last up to six months. Just one treatment every six months to keep balanced. The next step to treat your ED is three to several sessions of 20 to 30 minutes of new acoustic wave therapy, each a few days apart. It is mostly without discomfort, and non-surgical. Many patients show satisfactory improvement in their sexual functions. Patients upon each treatment can continue their normal activities.Stem Cell Therapy using your blood to use growth factor in your stem cells and injected. This procedure has been effective and restores normal functions. Valencia Medical Center offers Care Credit and in-house financing. For more information, please contact Valencia Medical Center at 661-222-9117. The office is located at 24159 Magic Mountain Parkway in Valencia.

Excerpt from:
Suffering from ED? Discover how our combined treatments of Hormone Balancing and FDA Approved Acoustic Wave Pulse Therapy Ends Your ED - Magazine of...

BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT – BioSpace

By Stem Cell Medical Center

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, on Thursday, May 7, 2020.

BrainStorms CEO, Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer and Preetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. EDT, Tuesday, May 5, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 1Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

ABOUT NUROWNNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

ABOUT BRAINSTORM CELL THERAPEUTICS INC.:BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

SAFE HARBOR STATEMENT:Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTSInvestor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: + 1.862.397.1860pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

More:
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT - BioSpace

Macomb County doctor charged health care fraud over COVID-19 treatments – Detroit Free Press

By Stem Cell Treatment

The founder of Allure Medical Spa, the Shelby Township business raided by federal officials last week, is accused of health care fraud that includes using the COVID-19 pandemic "as an opportunity to bill insurers for Vitamin-C infusions fraudulently represented as COVID-19 treatments and preventative measures."

Dr. Charles Mok is the only defendant listed in the 47-page complaint unsealed Tuesday in U.S. District Court in Detroit. The 56-year-old Washington Township man is charged with health care fraud and conspiracy to commit health care fraud in the complaint dated Friday.

His attorney, Mark Kriger, had no comment Tuesday morning.Mok is scheduled for an initial appearance in court at 1 p.m. Tuesday.

The complaint discusses multiple millions of dollars in billings to Medicare from Jan. 1, 2018 to April 7 of this year.

It alleges that Mok engaged in a scheme to defraud prior to and during the coronavirus pandemic through the submission of false and fraudulent claims to Medicare for payment related to the treatment of varicose veins.

The complaint also states he failed to observe appropriate protocols at the clinic to minimize the spread of the virus.

A cooperating witness, who is an employee, was aware of five employees who tested positive for the virus but continued to work and treat patients at Allure, according to the complaint.

Federal Bureau of Investigations evidence response team members head into the building where Allure Medical's office is in Shelby Township, Michigan on Thursday, April 23, 2020.The Federal Bureau of Investigations raided Allure Medical for an alleged "federal violation."(Photo: Eric Seals, Detroit Free Press)

FBI investigators raided the location near 26 Mile and Van Dyke last Thursday. TheU.S. Department of Health and Human Services was part of the task force.

More: FBI raids Allure Medical Spa in Shelby Township for alleged fraudulent COVID-19 treatments

A woman who answered the phone at the Allure Medical location the day of the raid she did not have anyone available to talk with a Free Press reporter. Messages left at the location and via email that day were not returned.

Allure Medical has eight locations in Michigan, as well as offices in Florida, Kentucky, North Carolina and South Carolina, according to its website.

It statedthe Shelby Township location offers varicose vein treatment, hormone replacement therapy, dermatology, stem cell therapy, cosmetics and weight loss services.

The building where Allure Medical's office is in Shelby Township, Michigan on Thursday, April 23, 2020.The Federal Bureau of Investigations raided Allure Medical for an alleged "federal violation."(Photo: Eric Seals, Detroit Free Press)

According to SRQ Magazine, Allure Medical was offering high-dose intravenous vitamin C therapy to front-line employees who are at risk of contracting the virus and to existing COVID-19 patients. Front-line workers are identified as those who include hospital staff, police and first responders, and grocery store employees.

The magazine quoted Mok as saying We are using high-dose IV vitamin C to help support people's immune systems and to help those with the virus recover quicker. We want to provide this treatment to those who need it, regardless of their ability to pay."

The magazine statedthat Allure Medical won't treat sick people at the same time as those who are healthy.

Contact Christina Hall: chall@freepress.com. Follow her on Twitter: @challreporter.

Read or Share this story: https://www.freep.com/story/news/local/michigan/macomb/2020/04/28/allure-medical-spa-shelby-covid-vitamin-c/3038801001/

Read more:
Macomb County doctor charged health care fraud over COVID-19 treatments - Detroit Free Press

The impact of the coronavirus on the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Volume Analysis, size, share and Key Trends…

By Stem Cell Treatment

Analysis of the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The recent market study suggests that the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is expected to grow at a CAGR of ~XX% between 2019 and 2029 and reach a value of ~US$XX by the end of 2029.

The study offers a microscopic view of the various segments and sub-segments of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market and accurately represents the data using informative tables, graphs, and figures. The objective of the report is to assist readers to make informed business decisions and improve their position in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market landscape post the COVID-19 pandemic.

Request Sample Report @https://www.mrrse.com/sample/18928?source=atm

Vital data enclosed in the report:

Segmentation Analysis of the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market study offers a detailed understanding of the consumption, demand, and pricing structure of each product.

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market report evaluates how the Platelet Rich Plasma and Stem Cell Alopecia Treatment is being utilized by various end-users.

By Region

The report offers valuable insights related to the growth prospects of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in different regions including:

Companies Mentioned in the Report

The report also profiles major players operating in the global platelet rich plasma & stem cell alopecia treatment market based on various attributes, such as company overview, financial overview, pipeline portfolio, product portfolio, business strategies, and recent developments. The players covered in the report include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy.

The global platelet rich plasma & stem cell alopecia treatment market has been segmented as below:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/18928?source=atm

Questions Related to the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Catered to in the Report:

Buy This Report @ https://www.mrrse.com/checkout/18928?source=atm

Read the original post:
The impact of the coronavirus on the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Volume Analysis, size, share and Key Trends...

Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) – Jewish Life News

By Stem Cell Treatment

GlobalStem Cell Therapy Market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this burgeoning sector. Readers will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe.

MarketInsightsReports has announced the addition of the Global Stem Cell Therapy Market Research Report 2020 The report focuses on global major leading players with information such as company profiles, product picture and specification.

Get Sample Copy of Stem Cell Therapy Market Report

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/inquiry?Mode=10

Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), request free sample for complete list of companies.

The leading players of industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among players will help the industry aspirants in planning their strategies.

Summary

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell Therapy market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell Therapy industry.

Stem Cell Therapy Market Segmentation by types, Applications and regions:

Market Segment by Type covers:

Autologous

Allogeneic

Market Segmented by Applications:

Musculoskeletal Disorder

Wounds & Injuries

Cornea

Cardiovascular Diseases

Others

Market Segment by Regions:

North America (the United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.)

Available [emailprotected] (Exclusive new year offer Flat 20%- Use code MIR 20):

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/discount?Mode=10

These segments are thoroughly evaluated on an individual basis and a team of analysts has ensured to give a crystal clear idea about various lucrative segments of the industry. This detailed analysis using segmentation by providing precise results on industry-related markets.

The report also analyzed the evolution of industry trends. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the industry.

Frequently Asked Questions about global market:

Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or 3 countries or nearly 40 analyst hours.

Note:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Visit complete report@

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026?Mode=10

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and Chinese and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

More:
Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) - Jewish Life News

Somatic Driver Mutations Leading to Endometrial Cancer Occur Early in Life – Cancer Therapy Advisor

By Stem Cell Treatment

Home Cancer Topics Gynecologic Cancer

Whole-genome DNA sequencing studies of normal endometrial glandulartissue have revealed the frequent presence of somatic driver mutations in cancer-relatedgenes. These findings were published in Nature.

While the acquisition of mutations overtime is believed to be a characteristic of all somatic cells, data are limitedon how it occurs in normal tissues.Nevertheless, the study authors noted that [t]he characterizationof the mutational landscapes of normal tissues isadvancing our understanding of the succession of intermediate neoplastic stages between normalcells and the cancers that originate fromthem.

One of the rationales for focusing on theendometrium of the uterus was related to its highly dynamic physiology duringthe reproductive years in response to fluctuating hormone levels, as well asits composition of stromal cells covered by a surface epithelium that iscontiguous with embedded glandular epithelium. Although the contiguity of thesurface epithelial sheet and the glandular tissue is disrupted duringmenstruation, it is subsequently restored by stem cells within retained embeddedglands.

In this study, 292 normal endometrialglands were isolated using laser-capture microdissection from 28 women between theages of 19 and 81 years. Comparisons of whole-exome DNA sequencing results forthese tissues with matched specimens of other types of normal tissue from thesame individual were used to identify somatic mutations in the endometrialglandular tissue. Corresponding data on patient age and parity allowed for theexploration of these factors on the rate and timing of somatic driver mutationsin normal glandular tissue of the endometrium.

Some of the keyfindings of this study included the following:

In their concluding remarks, the study authors noted that their results show that mutational landscapes differ markedly between normal tissues perhaps shaped by differences in their structure and physiology and indicate that the procession of neoplastic change that leads to endometrial cancer is initiated early in life.

Reference

Moore L, Leongamornlert D, Coorens THH, et al. The mutational landscape of normal human endometrial epithelium [published online April 22, 2020]. Nature. doi: 10.1038/s41586-020-2214-z

Please login or register first to view this content.

LoginRegister

Next post in Gynecologic CancerClose

Continue reading here:
Somatic Driver Mutations Leading to Endometrial Cancer Occur Early in Life - Cancer Therapy Advisor

Stem Cell Treatment Options | National Stem Cell Clinic

By Stem Cell Medicine

Find The Right Treatment Option Available For You

Dealing with chronic pain might have become routine, but it doesnt have to be your normal anymore. At National Stem Cell Clinic, our doctors have years of experience with regenerative medicine, improving the lives of patients just like you. We treat various areas of the body, including the following:

Degenerative discs often cause chronic neck pain. While surgery is a common solution, we have a less invasive solution with regenerative stem cells. After harvesting stem cells and combining them with growth factors, they are injected directly into the damaged portion of the neck. After about three weeks youll begin to notice results.

Learn more about stem cell therapy for neck pain

Stem cell therapy benefits patients with common shoulder injuries such as dislocations, arthritis, thoracic outlet syndrome, and rotator cuff issues. Unlike full joint replacement or other corrective shoulder surgeries, patients are able to get back to regular activity immediately.

Find out more about stem cell therapy for shoulder pain

Patients who have experienced chronic back pain may have been directed to physical therapy, pain meds, exercise, and other types of therapy. While these treatments assist in improving back function, full restoration rarely takes place. Now, regenerative medicine repairs damaged discs with the recreation of living tissues which are then injected into the damaged portion of the lower back, offering a significantly higher rate of full restoration.

About Our Stem Cell Therapy for Lower Back Pain

Back pain can be a debilitating condition of which people suffer for years on end. Many patients run through a gauntlet of tests and procedures and still find relief to be elusive. Fortunately, with new therapies and technologies, there is hope for sufferers of this chronic condition.

About Our Stem Cell Therapy for Back Pain

While osteoarthritis is a common reason for knee pain, it is often the result of another type of injury. This could include a fracture, a tear in the ligament, a muscle strain, or damage to the tendon. Minimally invasive stem cell injections can help patients suffering from this chronic pain to go from pain to self-recovery in just a few short months.

Learn about our stem cell treatment for knees

Like the knees, a lot of pain in patients is related to osteoarthritis. Individuals report immobility accompanied by painful swelling. Their hips may feel sharp, stabbing pains or dull aches. Other patients have pain caused by a traumatic injury. In either case, stem cell regeneration is a solution in which pain is minimized, tissues are rebuilt, and cartilage cells are replaced. After the procedure, the patients body works to reduce pain and inflammation with the regenerated cells.

Find out more about our stem cell treatments for hips

The elbow is a joint you regularly use, whether youre eating, playing a sport, playing an instrument, or simply using the remote control. If you want to avoid surgery or other invasive treatment options for your elbow pain, regenerative medicine is an option youll appreciate. Patients with golfers elbow, tennis elbow, arthritis, nerve entrapment, and similar elbow issues can get back to normal life immediately following the procedure.

More about our stem cell therapy for elbows

When you want a non-invasive treatment option for issues with your wrist, regenerative stem cells are the way to turn. Patients with trigger finger, instability, TFCC tears, arthritis, and other common wrist conditions can begin to function regularly after their own stem cells are used to repair damaged tissues within the wrist.

Read more about our treatment for wrist pain

When the median nerve in the hand is compressed, patients are often diagnosed with carpal tunnel syndrome. Basic pain, tingling, and numbness are frequently the resulting symptoms, though more severe nerve damage can occur. In any case, patients who are suffering from carpal tunnel can relieve symptoms with stem cell therapies, in which their damage is repaired with living, functional tissues.

Discover our treatment program for carpal tunnel

Your ankles and feet carry a heavy load, so when you begin to feel pain, its important to get treatment right away. Regenerative medicine can be used for ligament sprains, ankle instability, plantar fasciitis, tarsal tunnel syndrome, arthritis, and a variety of other conditions related to the ankle or foot.

More about our ankle and foot pain treatment with stem cells

Regenerative medicine has been found useful for those experiencing hair loss. Doctors reproduce and reintroduce the cells needed to the scalp. The patients previous hair begins to grow, making baldness a thing of the past.

Learn more about treatment for baldness

At National Stem Cell Clinic, we are happy to show you how regenerative medicine can improve your life. Contact us today!

Continue reading here:
Stem Cell Treatment Options | National Stem Cell Clinic

Dr Annalisa Jenkins on healthcare and biotech investments for family offices – Campden FB

By Stem Cell Medicine

The coronavirus pandemic has triggered a race for disruptive innovation in diagnostics, new therapies and novel vaccines, but the global life sciences industry was already expected to reach more than $2 trillion in gross value by 2023, up from $1.6 trillion before the crisis.

The pharmaceutical sector has long been attractive for family office investors, either directly or as part of their diversified portfolio. More than a quarter (27%) of families surveyed by Campden Wealth with UBS for The Global Family Office Report 2019 said they directly invested in health care and social assistance. It was the fourth most popular sector for families behind technology (49%), real estate and rental/leasing (42%) and finance and insurance (30%).

Dr Annalisa Jenkins MBBS, MRCP is a life sciences thought leader with more than 25 years of biopharmaceutical industry experience. The former surgeon lieutenant commander in the British Royal Navy during the Gulf Warsaid new entrepreneurial healthcare and biotech investment opportunities were opening for family investors from the disruptive revolutions in technology, stem cell therapy and mental health.

In an interview held before the coronavirus outbreak, the Chair of the Court of the London School of Hygiene and Tropical Medicine at the University of London, and chair or board member of Cellmedica, Vium and Cocoon Biotech, among others, tells CampdenFB which areas of investment she is personally interested in, the innovative trends she is seeing and what family investors need to know before entering the sector.

What is your outlook for investments in 2020?

Im hugely optimistic moving into the next decade. Whilst I think that one can always recognise that the geopolitical environment that we now operate in has markedly evolved in the last few years, whether that be the notion of risk, uncertainty, unpredictability, theres no doubt that has significantly evolved. Some of the driving factors behind that include global leadership, the climate evolution were living through, but ultimately the world of investment and the opportunities continue to be exciting.

When one looks across the field of health and innovation, were living in the so-called Fourth Industrial Revolution, and there is probably no sector that exemplarises that more than the health tech and life science sector. Today I would say the innovation coming out of our academic universities is as broad and as advanced as I have seen in the last 30 years of my career. I think the ability to access capital is just remarkable on a global basis, there are trillions of dollars that are out there in different parts of the economy, looking for innovation and looking for leaders to invest in. And, of course, we have a technology revolution that is ongoing, particularly driven by our ability to generate, curate and process data and deliver insights which are going to transform how we access and deliver healthcare and think about keeping people on a global basis well and healthy for longer and deliver improved therapeutics to reduce suffering.

I dont think I could be really more optimistic entering this new decade when it comes to thinking about the combination of equity with innovation and disruption and the evolution of the world I operate in.

What are the headwinds for investments in healthcare and life science?

The biggest concerns are around the well-publicised debates on pricing of technologies, particularly in the US, and how to ensure every individual can get equal access to health. Those two areas will continue to be debated and drive short-term cyclical uncertainty. There is no doubt global leadership, and that includes the US, recognise that for stable societies, access to universal healthcare and the ability of populations to be happy, healthy and flourishing lies as the centre of their political ambition.

Which healthcare investments are you excited about?

The cross-cutting themes that I am particularly excited about when it comes to technology are the ability for machine-learning and AI [artificial intelligence] to generate algorithms and therefore products that can be placed into the hands of individuals for them to manage, track and improve their health.

For example, there are products coming along in the area of mental health and wellness where individuals increasingly in the future will be able to access through their mobiles programmes and support services which will help them track their mood and maintain their wellness. We know that many diseases, for example, of the gastrointestinal system like irritable bowel syndrome, are markedly impacted by mental health and wellbeing. Interventions such as digital therapeutics, such as apps that are regulated and provided as therapeutics, are set to transform the way these diseases are managed. I am consistently looking for technologies that can be placed into the hands of individuals for self-directed and personalised prevention and care management.

Secondly, the ability of technology to improve the way we plan and conduct research and development on a global basis truly again going to be disrupted in the future by our ability to get large datasets in an ethical way to translate that into pre-clinical discoveries of new therapeutics. And then in the clinical setting to conduct novel clinical trials and to really change the way we bring new therapies to market, like new therapeutics, medical devices, diagnostics, biochemical markers across the board, so I am very interested in companies that are pursuing that.

Thirdly, the area of how do we optimise healthcare utilisation, the efficiency and the effectiveness, whether that be here in the UK in the NHS [National Health Service] or globally. Its absolutely clear that if we want to ensure affordable access to the top quality healthcare and outcomes for populations, were going to need embrace digital innovations, so companies that operate in that space are very attractive.

Those are the cross-cutting themes. If I look at the verticals, I would say to you, of course, there are very good investments to be made in the area of cancer and oncology. However, there is a marked amount of money in that space, its a little bit overpopulated. So for family offices and alternate sources of capital I would not be placing my money there at this point. I would be looking at counter cyclical trends, so areas that are perhaps now emerging. Areas such as womens health, otherwise known as Femtech, clearly now emerging as an area for investment and has been systematically underinvested in over the last 10-15 years. Cardiovascular disease continues to be the biggest killer and cause of illness on a global basis and yet it really hasnt received a lot of attention in investment. Were now seeing a wave of innovations and were starting to see more about the biology of heart disease, stroke and diabetes so again I would see that as an area of interest [as is] stem cells in therapeutics across a whole spectrum of diseases. Im particularly interested in Type 1 diabetes and the ability to generate beta cells for the production of insulin in patients with Type 1 diabetes. We are starting to see companies emerging and exploring that space so really stem cells and the cell therapy space, along with gene therapy is very interesting.

For family offices, the whole area of mental health and wellness is enormous and growing. The reason is its now becoming apparent people are talking about mental health and wellness in a way thats reducing stigma and then allowing money to flow into this space. How we deal with the human brain and preserving the health and wellness of the brain, both from an emotional and physical point of view, whether that be the prevention of degenerative brain disorders like dementia or the management of anxiety and all the related diseases known as depression, is a very interesting space for investment and its where I am investing in a lot.

How can family offices enter and succeed in the healthcare and biotech investment market?

Its extremely difficult as a family office to make an initial move into the sector, largely because its extremely complicated and it really rather depends on what the investment goals are and the returns that are desired. The sector is highly fragmented and family offices have traditionally and largely invested in the more sustainable, long-term world of pharma as part of a general equity portfolio. Were talking about a very different sector which is largely based on entrepreneurship, a lot of risk and deep science, so I think the first thing to say is that family offices, before moving into or when in this space, should ensure they have the access to the right expertise around the table. They can gain that either through their own networks of advisers or by participating through investments in a fund.

Often the best way to get started is to find a fund that meets the investment criteria of a family office and to start to invest through that. Not through a traditional VC fund, there are number of funds coming together with the sole purpose of accessing family offices, sovereign wealth funds, alternate sources of capital and then investing through that because its really important in the risky healthcare and life science sector to have a portfolio view that is very strategically put together. You have to be prepared to fail and to be prepared to be a long-term patient investor thats willing to along five-to-seven years for the ride.

Go here to see the original:
Dr Annalisa Jenkins on healthcare and biotech investments for family offices - Campden FB

→←